|1.||White, Nicholas J: 20 articles (01/2015 - 09/2003)|
|2.||Rosenthal, Philip J: 15 articles (09/2015 - 03/2003)|
|3.||Whitty, Christopher J M: 14 articles (01/2015 - 09/2005)|
|4.||Snow, Robert W: 11 articles (01/2011 - 12/2003)|
|5.||Staedke, Sarah G: 10 articles (05/2015 - 01/2006)|
|6.||Chandler, Clare I R: 10 articles (05/2015 - 01/2008)|
|7.||Lengeler, Christian: 10 articles (01/2011 - 01/2005)|
|8.||Fidock, David A: 9 articles (09/2014 - 10/2002)|
|9.||Looareesuwan, S: 9 articles (12/2004 - 06/2000)|
|10.||Wirth, Dyann F: 8 articles (09/2015 - 01/2009)|
03/01/2015 - "The potent gametocytocidal activity of DANQ and IBI coupled with their efficacy against asexual parasites provides leads for the development of antimalarials with the potential to prevent both the symptoms and the spread of malaria. "
01/01/2002 - "Yearly residual house spraying performed for 5 years (1993-1998) and the availability of antimalarial drugs reduced malaria transmission to very low levels, with improvement in parasitologic and entomologic indexes. "
12/01/1995 - "It is recommended that blood samples from prospective blood donors be examined for malaria parasites and that recipients of malaria-infected blood samples be given a curative regimen of antimalarials."
08/01/2003 - "Although antimalarial drugs have been developed primarily to treat malaria, they are also beneficial for many dermatological, immunological, and rheumatological diseases, for which they are mostly used today in the Western world. "
01/01/2008 - "Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials."
|2.||Falciparum Malaria (Plasmodium falciparum Malaria)
01/01/2008 - "The spread of resistance to antimalarial drugs has required changes in the recommended first-line treatment for falciparum malaria in almost all regions. "
01/01/2003 - "falciparum malaria and compared with other commonly used antimalarial agents has an improved tolerability profile, and, overall, a more convenient dosage regimen, particularly in the post-travel period."
06/01/2005 - "This collaborative cross-border study was performed to determine the therapeutic efficacy of antimalarial drugs used by the National Programmes for falciparum malaria along the eastern Indo-Nepal border where there is unregulated population movement across the border. "
09/01/2003 - "Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand."
08/01/2003 - "Therapeutic efficacy of anti-malarials in Plasmodium falciparum malaria in an Indo-Myanmar border area of Arunachal Pradesh."
06/01/2006 - "These patients, who are often immunocompromised, may receive a secondary advantage from these antimalarials, which may provide some protection against staphylococci (amongst the most important human pathogens causing many superficial and systemic infections) and E. "
01/01/2000 - "An inevitable consequence of the prolonged life-span and relative metabolic stasis of the mature gametocytes of Plasmodium falciparum is that they are not cleared by most antimalarials, and few antimalarials block infection in the mosquito vector. "
06/01/1998 - "Provided new infections are excluded, the 28-day clearance rate can also be used to determine the efficacy of antimalarial drugs in highly endemic areas, and adds to our knowledge of drug resistance and dynamics of infections in people living in such areas."
09/01/2003 - "A standardised protocol has been developed by World Health Organization (CDS/RBM/2002) to assess the efficacy of common antimalarials in the treatment of clinically manifested infection with uncomplicated P. "
01/01/2011 - "A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs."
|4.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
10/14/1988 - "No recent study has been published on the efficacy of antimalarial drugs in the treatment of systemic lupus erythematosus (SLE). "
07/01/2009 - "Systemic lupus erythematosus in the elderly: antimalarials in disease remission."
06/01/1996 - "The efficacy of antimalarials in systemic lupus erythematosus."
02/01/1993 - "The efficacy of antimalarials in systemic lupus erythematosus."
10/14/1988 - "Efficacy of antimalarials in systemic lupus erythematosus."
|5.||Cutaneous Lupus Erythematosus
03/01/2009 - "Treatment with antimalarial drugs resulted in a significant reduction in the Cutaneous Lupus Erythematosus Disease Area and Severity Index score, from 4 (range, 2-8) at baseline to 1 (range, 0-6) after 3 months of therapy (P < .001). "
04/01/2015 - "Interaction between smoking and efficacy of antimalarials, the mainstay of treatment for cutaneous lupus erythematosus (CLE), remains controversial. "
06/01/2012 - "Smoking seems to inhibit the therapeutic efficacy of antimalarials when treating cutaneous lupus erythematosus (CLE), but the reason behind this observation is unclear. "
01/01/1998 - "There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. "
08/01/2015 - "Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus."
|6.||Antimalarials (Antimalarial Agents)
|8.||Immunosuppressive Agents (Immunosuppressants)
|1.||Drug Therapy (Chemotherapy)